This work was supported by National Institutes of Health grant RO1 AI067979 to NWA. 
YK is recipient of undergraduate fellowship from the Howard Hughes Medical Institute/University of Maryland College Park.

All experimental procedures were conducted in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health and were approved by University of Maryland&#39;s IACUC. All steps described in sections 1 through 4 should be carried out aseptically inside biological laminar flow cabinets. Personal protection should be used, and caution should be exercised during handling of live Leishmania parasites throughout all stages of experimentation.
1. Isolation and Differentiation of Bone Marrow-derived Macrophages (BMMs)8,30,31
<ol>
	<li>Day 0: Sacrifice 4 - 6-week-old female C57BL/6 or BALB/c mouse in a CO2 chamber and confirm death via cervical dislocation. Ensure sterilization of scissors and forceps by keeping them soaked in 70% ethanol. Spray gloves with 70% ethanol to allow sterile handling throughout the bone marrow cell isolation process.</li>
	<li>Secure sacrificed mouse to dissection board by pinning its forelimbs and disinfect by spraying copiously with 70% ethanol.</li>
	<li>Make a small incision (about 1 cm) with scissors near the hip joint. Carefully insert scissors under the skin to separate the underlying muscle and cut the skin all the way around the hip joint. 
	NOTE: The dissection board may be rotated to allow improved access to the hip joint.</li>
	<li>Carefully deglove skin from the leg by pulling towards the ankle and remove. Cut the foot off at the ankle, being very careful to cut at or below the ankle joint to leave the tibia fully intact. 
	NOTE: The fibula at this stage is loosely attached and can be easily separated with the forceps.</li>
	<li>Manually locate the hip joint by manipulating the femur to identify the point of rotation. Carefully use scissors to sever the leg above the hip joint to leave the proximal head of the femur intact.</li>
	<li>Remove as much muscle and connective tissue as possible from the leg with scissors. Remove any remaining skin from the ankle and any excess bone material above the hip joint.</li>
	<li>Place the cleaned leg bones in sterile RPMI supplemented with penicillin/streptomycin (1% final concentration) in a Petri dish on ice.</li>
	<li>Repeat steps 1.4 through 1.6 to isolate tibia and femur from the other hind leg.</li>
	<li>Remove any remaining muscle and connective tissue from the bones soaking in RPMI using sterilized forceps and sterile #10 blade.</li>
	<li>Place bones on the Petri dish lid. Cut the tibia carefully with the blade immediately above the ankle joint to access the marrow. Remove the tibia from the rest of the leg by cutting immediately below the knee joint.</li>
	<li>Draw 10 mL sterile RPMI supplemented with penicillin/streptomycin (1% final concentration) into a 10-mL syringe and attach a 25G needle.</li>
	<li>Hold the tibia firmly with forceps, vertically over a 50-mL conical tube on ice. Use the syringe to gently inject approximately 5 mL RPMI into the end of the bone to flush the bone marrow out of the other end into the conical tube. Flush the bone marrow with a total of 10 mL RPMI until the bone turns white. 
	NOTE: After thorough flushing, the bone should turn white. If not, continue flushing to remove marrow. The distal end of the tibia may need to be trimmed back with the blade if it is too narrow to insert the needle.</li>
	<li>Cut the femur immediately above the knee joint and immediately below the hip joint to expose both ends of the bone to access the marrow. Flush bone marrow from the femur with a total of 10 mL RPMI in the same fashion as the tibia.</li>
	<li>Repeat cleaning and flushing steps 1.6 through 1.13 with the remaining bones and collect the bone marrow flushed cells in a single 50 mL conical tube 
	NOTE: If a bone breaks at any point during dissection prior to bone flushing, do not use the marrow from this bone.</li>
	<li>Centrifuge the conical tube used to collect bone marrow flushed from all four bones for 10 min at 4 &#176;C at 300 x g.</li>
	<li>Place 60 mL of sterile BMM medium (RPMI with a final concentration of 20% FBS, 1% penicillin/streptomycin, 1.2 mM Na-pyruvate, 25 &#181;g/mL human M-CSF) into a 175 cm2 cell culture flask with filter cap.</li>
	<li>Discard the supernatant following centrifugation and resuspend the cell pellet by gentle up and down pipetting using 5 mL of BMM medium from the flask.</li>
	<li>Transfer cell suspension to the culture flask and rinse the conical tube twice with BMM medium from the culture flask to ensure maximal cell recovery. Ensure cell suspension is thoroughly mixed into medium and distribute 30 mL from the initial 175 cm2 cell culture flask to a second 175 cm2 cell culture flask with filter cap.</li>
	<li>Incubate both flasks containing 30 mL cell suspension each overnight at 37 &#176;C, 5% CO2 to allow separation of any contaminating fibroblasts, resident macrophages, and other adherent cells.</li>
	<li>DAY 1: Transfer the supernatant containing undifferentiated bone marrow cells from flasks to 100 mm x 15 mm non-TC-treated polystyrene Petri dishes at approximately 10 mL/dish and incubate at 37 &#176;C, 5% CO2. Discard the flasks.</li>
	<li>DAY 3 or 4: Add an additional 5 mL BMM medium (pre-warmed to 37 &#176;C) to each Petri dish and continue incubation at 37 &#176;C, 5% CO2.</li>
</ol>
2. Plating BMMs on Coverslips for Infection (DAY 7 or 8)
<ol>
	<li>Prepare 6-well tissue culture plates by placing four (4) sterile 12 mm glass coverslips (autoclaved and stored in a closed glass container) in the bottom of each empty well. 
	NOTE: Pick each sterile 12 mm coverslip up with an aspirating tip fitted to a vacuum line. Place coverslips into the wells without overlap, releasing at the desired position by pinching the tube to interrupt vacuum.</li>
	<li>Aspirate media (and any non-adherent cells) from Petri dishes coated with adherent bone marrow derived macrophages and gently rinse adherent cells 2x with sterile Dulbecco&#39;s Phosphate buffered saline without calcium and magnesium chloride (PBS -/-) pre-warmed to 37 &#176;C.</li>
	<li>Add dropwise, 5 mL sterile 1x PBS -/- with a final concentration of 1 mM EDTA to each Petri dish and incubate for 5 min at 37 &#176;C to detach adherent BMMs. Verify that the cells are detached using a microscope.</li>
	<li>Collect all detached cells suspended in 1x PBS -/- supplemented with 1 mM EDTA in a 50 mL conical tube. Rinse each dish 2x with 5 mL PBS -/- and add to cell suspension pool. 
	NOTE: Cell suspension may be diluted with additional PBS -/- to protect macrophages from EDTA toxicity during the collection process.</li>
	<li>Centrifuge at 300 x g for 10 min at 4 &#176;C. Discard supernatant and resuspend macrophages in 5 - 10 mL BMM medium by pipetting. Place resuspended cells on ice to prevent attachment to tubes and clumping.</li>
	<li>Count viable cells using Trypan blue exclusion in the hemocytometer. 
	NOTE: To count BMM cells resuspended in 5 mL medium, a dilution-mix of 25 &#181;L cell suspension in 445 &#181;L PBS -/- and 30 &#181;L 0.4% Trypan blue solution typically allows easy quantification in a hemocytometer (taking into account a 20x dilution factor for the final calculation). Count only cells that did not get stained with Trypan blue (viable cells). The volume of cell suspension may be altered if this mixture is too concentrated or diluted. In general, the yield of BMM per preparation varies between 2 x 107 and 5 x 107 cells from a single mouse.</li>
	<li>Prepare the cell suspension in BMM medium at desired plating concentration (5 x 105/mL) and disperse suspension to 6 well plates in 2 mL medium per well so that each well receives 1 x 106 macrophages. 
	NOTE: This is a critical step that ensures every well gets the adequate number of macrophages to cover the coverslips uniformly. Check that coverslips in wells are not overlapping or floating in the medium. If so, gently adjust with a sterile pipette tip.</li>
	<li>Incubate overnight at 37 &#176;C, 5% CO2.</li>
</ol>
3. Purification of Infective Forms of L. amazonensis
NOTE: Prepare Leishmania for infections- purify metacyclic promastigotes from stationary promastigote cultures8,13, or differentiate promastigotes in culture into amastigote form using standard L. amazonensis axenic differentiation protocol6,8.
<ol>
	<li>Purification of Leishmania metacyclic promastigotes using density gradient media(Materials)33
	<ol>
		<li>Prepare 40% stock solution of density gradient media in sterile, endotoxin-free water.</li>
		<li>Dilute density gradient solution in 10x M199 medium (without serum) to prepare 10% concentration in the M199 medium.</li>
		<li>Filter all solutions through 0.22 &#181;m filter. 
		NOTE: Stock solutions can be stored at 4 oC in darkness for no longer than 1 month.</li>
		<li>Add 2 mL of 40% density gradient media solution in the bottom of a 15-mL conical centrifuge tube.</li>
		<li>Layer 2 mL of 10% density gradient media solution in M199 on top of the 40% density gradient media layer carefully, using a Pasteur pipette to avoid any mixing between the two layers.</li>
		<li>Collect 1 x 109 parasites from stationary-phase culture by centrifugation at 1,900 x g for 10 min.</li>
		<li>Resuspend cells in 6 mL Dulbecco&#39;s Modified Essential Medium (DMEM).</li>
		<li>Layer 2 mL of the cell suspension directly on top of the 10% density gradient media layer, gently, using a Pasteur pipette to avoid mixing between layers.</li>
		<li>Centrifuge the gradient for 10 min at 1,300 x g at room temperature. 
		NOTE: Due to differences in physical properties between Leishmania species, centrifugation conditions for each might have to be slightly adjusted to ensure maximum yield.</li>
		<li>Collect parasites (enriched in metacyclic promastigote form) from the band formed at the upper 10% density gradient media boundary (interface between the 0% and 10% density gradient media layers).</li>
		<li>Dilute parasites with one volume of DMEM and collect by centrifugation (1,900 x g for 10 min at room temperature).</li>
		<li>Resuspend in 500 &#181;L DMEM medium and count in a hemocytometer to quantify yield.</li>
	</ol>
	</li>
	<li>Generation of L. amazonensis amastigotes under axenic culture conditions (low pH / elevated temperature)6,8,13
	<ol>
		<li>Mix 5 mL of log-phase promastigote culture (pH 7.4 at 26 oC) with an equal volume of amastigote medium (pH 4.5), using 25 cm2 flasks (total 10 mL medium) and incubate at 26 &#176;C overnight.</li>
		<li>Shift the flask from 26 &#176;C to 32 &#176;C.</li>
		<li>After 3 or 4 days, split culture 1:5 in amastigote media at 32 &#176;C.</li>
		<li>Check the parasites in the next 3 - 4 days (maximum 7 days) to see if they are ready for use in infections. 
		NOTE: Healthy axenic amastigotes should have an oval shape, without visible flagella. Partially differentiated amastigotes have a large oval shape with short flagella. The culture should not have a lot of clumps - many clumps are an indication of non-growing, dying parasites. The amastigote culture can be split 1:5 and maintained for a maximum of 3 weeks.</li>
	</ol>
	</li>
</ol>
4. Infection with L. amazonensis
<ol>
	<li>Dilute parasite suspensions according to desired MOI (usually 3-5 metacyclic promastigotes per macrophage [MOI of 1:3 or 1:5] and 1 amastigote per macrophage [MOI 1:1]). Add Leishmania in PBS -/- in a volume of 50 - 100 &#181;L to each well already containing 2 mL medium.</li>
	<li>Incubate BMMs for 1 h with amastigotes and 3 h with metacyclic promastigotes at 34 oC for infection. 
	NOTE: Optimal infection temperature may vary by species.</li>
	<li>Following incubation, thoroughly wash away free parasites in each well 3x with 2 mL PBS -/- pre-warmed to 37 &#176;C. 
	NOTE: Disperse PBS gently to ensure that coverslips do not float over each other. Gently swirl the plate and then aspirate out the liquid. Use separate aspirating tip if using multiple strains of parasites to avoid cross-contamination.</li>
	<li>Fix 1 h or 3 h time-point samples by incubating each well with 1.5 - 2 mL of 2% PFA in PBS -/- for 10 min. Wash 3x with PBS -/-. Do not aspirate last wash and refrigerate plates containing coverslips in PBS until staining.</li>
	<li>Add 2 mL fresh BMM medium to each well on plates for further time-points and incubate at 34 &#176;C.</li>
	<li>Fix remaining time-points as desired as described in step 4.3, and refrigerate plates until staining.</li>
</ol>
5. DAPI Staining and Coverslip Mounting
<ol>
	<li>Aspirate PBS from wells containing coverslips and add 1.5 mL PBS -/- with 0.1% non-ionic detergent. Incubate for 10 min at room temperature, followed by 3x wash with 2 mL PBS -/-.</li>
	<li>Add 1 mL PBS -/- with 2 &#181;g/mL DAPI (diluted from 5 mg/mL stock solution in water) to wells containing coverslips and incubate for another 1 h at room temperature. 
	NOTE: The incubation time with DAPI is critical for proper visualization of intracellular Leishmania parasites. Macrophage nuclei stain rapidly, due to their larger size and DNA content but staining of nuclei of the intracellular parasites is slower. Thus, extending incubation time beyond what is required to visualize the BMM nuclei is necessary to allow DAPI to permeate through and the parasite plasma membrane, and the parasite nuclear membrane. With proper DAPI stain, the mitochondrial kinetoplast DNA near the flagellar pocket of the parasite can also be visualized, in addition to the nuclear DNA.</li>
	<li>Wash each well containing coverslips 3x with 2 mL PBS -/- and then lift and flip coverslips with forceps to place the cell side down and mount on glass microscope slides with a commercially available antifade mounting reagent. 
	NOTE: Coverslips are extremely fragile and need cautious handling. Avoid putting pressure on them, especially against the sidewall of the wells when lifting. Adding a few drops of PBS -/- reduces surface tension between the coverslip and well and facilitates the lifting process. A fine gauge needle may be used to assist in prying the coverslips from the bottom of the well. After placing a coverslip on the slide, gently press down with forceps to push out any air bubbles in the mounting media. If a coverslip is broken or has possibly flipped during the lifting process, do not remount; simply use the spare fourth coverslip.</li>
	<li>Refrigerate slides until quantification.</li>
</ol>
6. Infection Quantification
<ol>
	<li>Examine DAPI-stained slides under a fluorescence microscope by focusing on macrophages using 100X&#160;objective lens with immersion oil (excitation at 358 nm; optimal emission at 461 nm). 
	Ensure that focus is on the layer of macrophages between the glass slide and coverslip.</li>
	<li>Quantify the number of macrophages (large nuclei stained with DAPI) and the number of smaller amastigote nuclei clustered around each macrophage nucleus (see Figure 2A, DAPI) for each field of vision, using a manual counter. 
	NOTE: Amastigote nuclei may not all be visible in one plane of focus due to their small size. Count those that are visible when focused on macrophage nuclei, and then use fine focus to check for parasite nuclei in planes above and below the macrophage nuclei.</li>
	<li>Move to another field of vision to repeat quantification. Use a separate counter key to track the number of fields counted. Move through visual fields in parallel rows across each coverslip, to prevent counting overlap.</li>
	<li>Quantify a minimum of 200 macrophages per coverslip. Quantify each time-point of infection in triplicate (3 coverslips). Count the fourth coverslip if one of the previous is not suitable for counting due to coverslip overlap, poor mounting, glass breakage, etc. 
	NOTE: If 200 macrophages cannot be counted on any one coverslip, count the spare fourth.</li>
	<li>Calculate infection rates as amastigotes/macrophage or amastigotes/100 macrophages and determine percent infected macrophages from the raw quantification data.</li>
</ol>

The authors declare they have no competing financial interests,

The quantitative data produced by the BMM infection assay described above, allows investigators to obtain rates of infection and a reliable determination of changes in virulence properties in a relatively shorter time period (maximum 2 weeks, compared to the 2 months required for in vivo experiments). This method relies on the DNA specific dye DAPI, which specifically stains macrophage and parasite nuclei, and allows rapid identification and quantification of infected cells. In comparison, other stains such as G...

Leishmaniasis refers to a broad spectrum of human diseases caused by protozoan parasite species of the genus Leishmania. Approximately 12 million people are currently infected with Leishmania worldwide, and more than 350 million are at risk. The disease pathology depends on the Leishmania species and on host factors, and symptoms vary from innocuous self-healing skin lesions to lethal visceralizing forms. If untreated, visceral leishmaniasis is fatal, ranking only after malaria as the deadliest human disease caused by infection with a protozoan parasite1. In spite of the wide-ranging differences in disease pathology and symptoms, all Leishmania species have a digenic life-cycle alternating between promastigote and amastigote stages inside insect and vertebrate hosts, respectively. Inside vertebrates, Leishmania target host macrophages for invasion and induce the formation of parasitophorous vacuoles (PVs), acidic compartments with properties of phagolysosomes where the highly virulent amastigote forms replicate. Amastigotes persist in host tissues during chronic infections and can be passed forward to uninfected sandflies, completing the transmission cycle. Therefore, in the context of human disease development, amastigotes are the most important Leishmania lifecycle form2. Investigating how amastigotes replicate inside macrophage PVs is critical for understanding Leishmania virulence3,4,5,6,7 and for the development of novel efficacious therapies.
We describe here a method regularly used by our laboratory to study Leishmania infection and replication in bone marrow-derived macrophages (BMMs), which involves quantitative assessment of the number of intracellular Leishmania over time. The process involves harvesting of monocytes from mouse bone marrow and differentiation to macrophages in culture, in vitro infection with infective forms (metacyclic promastigotes or amastigotes) of Leishmania and quantification of the number of intracellular parasites at every 24 h interval for a period of 72 - 96 h following infection. This assay has been used in our laboratory to determine the impact of several environmental factors and parasite genes, including identification of the critical role of iron in promoting L. amazonensis virulence that was further validated by footpad lesion development studies in mice6,8,9,10,11,12,13,14,15. Since all pathogenic Leishmania species establish their replicative niche inside host macrophages, this assay can be used universally for virulence determinations in all Leishmania species.
Performing BMM infections allows analysis of host-parasite interactions at the single cell level, and thus a more extensive understanding of how Leishmania parasites interact with their preferred host microenvironment, the PVs of macrophages. Macrophage infection assays have been successfully used by multiple groups16,17,18,19,20,21,22 to explore functions of both the host macrophage and Leishmania specific genes, and their potential involvement in the complex interplay that characterizes intracellular infection. BMM infections allow quantification of parasite growth as a read-out of the impact of host factors that influence intracellular survival, such as microbicidal nitric oxide production, generation of reactive oxygen species and other adverse conditions encountered inside the lysosome-like PVs23. Macrophage infection assays have also been utilized to identify potential anti-leishmanial drug leads for therapeutic development13,24.
The in vitro nature of BMM infections provides several advantages over other methods to assess Leishmania virulence. However, several previous studies examining mechanisms of intracellular parasite survival over time did not quantify infection as a rate20,21,24. Furthermore, many studies focused on following in vivo infections over time did so by measuring cutaneous lesion size and other physiological symptoms that are only indirectly related to parasite replication25,26,27. In vivo infection is a stringent approach to assess parasite virulence, but lesion size measurements based on footpad swelling alone are often inadequate, as they reflect the inflammatory response in infected tissues and not the absolute number of parasites. For this reason, footpad lesion development assays have to be followed by quantification of the parasite load in infected tissues, a procedure that requires lengthy limiting dilution assays28. Additionally, in vivo studies often involve sacrificing multiple animals at different points in time to extract tissues of interest6,8,9,10,11,13. In contrast, large numbers of BMMs can be obtained from just one animal, and these cells can be plated under conditions that allow assessment of infection at various points in time. Furthermore, compared to in vivo studies, performing in vitro BMM infections allows greater control over experimental conditions. Quantifying the macrophages to be infected along with the parasites themselves allows precise control of the multiplicity of infection (MOI) and of culture conditions. Fine control over these factors can be key in identifying characteristics of discrete cellular pathways and in understanding their impact on the course of infection.
Given these advantages, it is somewhat surprising that very few groups studying Leishmania virulence have so far taken full advantage of quantitative assessment of intracellular replication in macrophages. In this article, we discuss common pitfalls that may be hampering the more extensive utilization of this assay, and provide a step-by-step protocol to facilitate its proper implementation. Considering its precision and versatility, the BMM infection assay we describe here can not only be utilized to explore host-pathogen interactions influencing Leishmania virulence, but also to study other microorganisms that replicate inside macrophages29. Importantly, this assay can also be developed as a rapid and economical pre-clinical screening method for anti-leishmanial drug development.

<table><tbody><tr><td>6 well cell culture plate</td><td>Cellstar</td><td>657160</td><td></td></tr><tr><td>Adenine</td><td>Acros Organics</td><td>AC147440250</td><td></td></tr><tr><td>Aerosol Barrier Pipet Tips (100-1000 &amp;mu;L)</td><td>Fisherbrand</td><td>02-707-404</td><td></td></tr><tr><td>Aerosol Barrier Pipet Tips (20-200 &amp;mu;L)</td><td>Fisherbrand</td><td>02-707-430</td><td></td></tr><tr><td>Aerosol Barrier Pipet Tips (2-20 &amp;mu;L)</td><td>Fisherbrand</td><td>02-707-432</td><td></td></tr><tr><td>Bard-Parker Rib-Back Carbon Steel Surgical Blade #10</td><td>Aspen Surgical</td><td>371110</td><td></td></tr><tr><td>BD Luer-Lok Tip 10 mL Syringe</td><td>Becton Dickinson (BD)</td><td>309604</td><td></td></tr><tr><td>BD Precisionglide Needle, 25G&amp;nbsp;</td><td>Becton Dickinson (BD)</td><td>305124</td><td></td></tr><tr><td>Cell Culture Dish 35 mm x 10 mm</td><td>Cellstar</td><td>627 160</td><td></td></tr><tr><td>Cell Culture Flask</td><td>Cellstar</td><td>660175</td><td></td></tr><tr><td>Cover Glasses: 12 mm circles</td><td>Fisherbrand</td><td>12-545-80</td><td></td></tr><tr><td>DAPI (4&#039;,6-Diamidino-2-Phenylindole, Dihydrochloride)</td><td>Invitrogen</td><td>D1306</td><td></td></tr><tr><td>D-Biotin</td><td>J.T. Baker</td><td>C272-00</td><td></td></tr><tr><td>EDTA</td><td>Sigma Aldrich</td><td>EDS</td><td></td></tr><tr><td>Ethyl alcohol 200 proof</td><td>Pharmco-AAPER</td><td>111000200</td><td></td></tr><tr><td>Falcon 100 mm x 15 mm non-TC-treated polystyrene Petri dish</td><td>Corning</td><td>351029</td><td></td></tr><tr><td>Fetal Bovine Serum</td><td>Seradigm</td><td>1500-500</td><td></td></tr><tr><td>Ficoll400</td><td>Sigma Aldrich</td><td>F8016</td><td></td></tr><tr><td>Fluorescence Microscope</td><td>Nikon</td><td>E200</td><td></td></tr><tr><td>Goat anti-mouse IgG Texas red</td><td>Invitrogen</td><td>T-862</td><td></td></tr><tr><td>Goat anti-rabbit IgG AlexaFluor488</td><td>Invitrogen</td><td>A-11034</td><td></td></tr><tr><td>Hemin</td><td>Tokyo Chemical Industry Co. LTD</td><td>H0008</td><td></td></tr><tr><td>HEPES (1M)</td><td>Gibco</td><td>15630-080</td><td></td></tr><tr><td>Isoton II Diluent</td><td>Beckman Coulter</td><td>8546719</td><td></td></tr><tr><td>L-Glutamine</td><td>Gemini</td><td>400-106</td><td></td></tr><tr><td>Medium 199 (10X)</td><td>Gibco</td><td>11825-015</td><td></td></tr><tr><td>Na pyruvate (100 mM)</td><td>Gibco</td><td>11360-070</td><td></td></tr><tr><td>Paraformaldehyde</td><td>Alfa Aesar</td><td>43368</td><td></td></tr><tr><td>Penicillin/Streptomycin</td><td>Gemini</td><td>400-109</td><td></td></tr><tr><td>Phosphate Buffered Saline (-/-)</td><td>ThermoFisher</td><td>14200166</td><td></td></tr><tr><td>Polypropyline conical Centrifuge Tubes 15 mL</td><td>Cellstar</td><td>188 271</td><td></td></tr><tr><td>Polypropyline conical Centrifuge Tubes 50 mL</td><td>Cellstar</td><td>227 261</td><td></td></tr><tr><td>ProLong Gold antifade reagent</td><td>ThermoFisher</td><td>P36930</td><td></td></tr><tr><td>Rat anti-mouse Lamp-1 antibody</td><td>Developmental Studies Hybridoma Bank</td><td>1D4B</td><td></td></tr><tr><td>Recombinant Human M-CSF</td><td>PeproTech</td><td>300-25</td><td></td></tr><tr><td>Reichert Bright-Line&amp;nbsp; Hemocytometer&amp;nbsp;</td><td>Hausser Scientific</td><td>1492</td><td></td></tr><tr><td>RPMI Medium 1640 (1X)</td><td>Gibco</td><td>11875-093</td><td></td></tr><tr><td>Triton X-100 Surfactant</td><td>Millipore Sigma</td><td>TX1568-1</td><td></td></tr><tr><td>Trypan Blue</td><td>Sigma Aldrich</td><td>T8154</td><td></td></tr><tr><td>Delicate Scissors, 4 1/2&quot;</td><td>VWR</td><td>82027-582</td><td></td></tr><tr><td>Dissecting Forceps, Fine Tip</td><td>VWR</td><td>82027-386</td><td></td></tr><tr><td>Microscope Slides</td><td>VWR</td><td>16004-368</td><td></td></tr><tr><td>Z1 Coulter Particle Counter, Dual Threshold</td><td>Beckman Coulter</td><td>6605699</td><td></td></tr></tbody></table>

quantification of intracellular growth inside macrophages is a fast and reliable method for assessing the virulence of leishmania parasites

The lifecycle of Leishmania, the causative agent of leishmaniasis, alternates between promastigote and amastigote stages inside the insect and vertebrate hosts, respectively. While pathogenic symptoms of leishmaniasis can vary widely, from benign cutaneous lesions to highly fatal visceral disease forms depending on the infective species, all Leishmania species reside inside host macrophages during the vertebrate stage of their lifecycle. Leishmania infectivity is therefore directly related to its ability to invade, survive and replicate within parasitophorous vacuoles (PVs) inside macrophages. Thus, assessing the parasite&#39;s ability to replicate intracellularly serves as a dependable method for determining virulence. Studying leishmaniasis development using animal models is time-consuming, tedious and often difficult, particularly with the pathogenically important visceral forms. We describe here a methodology to follow the intracellular development of Leishmania in bone marrow-derived macrophages (BMMs). Intracellular parasite numbers are determined at 24 h intervals for 72 - 96 h following infection. This method allows for a reliable determination of the effects of various genetic factors on Leishmania virulence. As an example, we show how a single allele deletion of the Leishmania Mitochondrial Iron Transporter gene (LMIT1) impairs the ability of the Leishmania amazonensis mutant strain LMIT1/&#916;Lmit1 to grow inside BMMs, reflecting a drastic reduction in virulence compared to wild-type. This assay also allows precise control of experimental conditions, which can be individually manipulated to analyze the influence of various factors (nutrients, reactive oxygen species, etc.) on the host-pathogen interaction. Therefore, the appropriate execution and quantification of BMM infection studies provide a non-invasive, rapid, economical, safe and reliable alternative to conventional animal model studies.

Leishmania has two infective forms - metacyclic promastigotes that differentiate from procyclic promastigotes at the stationary phase of culture, and amastigotes, which are the intracellular stages (Figure 1). In some Leishmania species such as L. amazonensis, amastigotes can also be differentiated in axenic culture by shifting the promastigote cells to lower pH (4.5) and elevated temperature (32 &#176;C), conditions similar to thos...

Watch this Scientific Journal Video about Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites at JoVE.com

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

All pathogenic Leishmania species reside and replicate inside macrophages of their vertebrate hosts. Here, we present a protocol to infect murine bone marrow-derived macrophages in culture with Leishmania, followed by precise quantification of intracellular growth kinetics. This method is useful for studying individual factors influencing host-pathogen interaction and Leishmania virulence.

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

The lifecycle of Leishmania, the causative agent of leishmaniasis, alternates between promastigote and amastigote stages inside the insect and vertebrate ...

quantification-intracellular-growth-inside-macrophages-is-fast

Universidad de Cartagena UDEC

Research

JoVE Journal

Immunology and Infection

10.4K Views.  University of Maryland. All pathogenic Leishmania species reside and replicate inside macrophages of their vertebrate hosts. Here, we present a protocol to infect murine bone marrow-derived macrophages in culture with Leishmania, followed by precise quantification of intracellular growth kinetics. This method is useful for studying individual factors influencing host-pathogen interaction and Leishmania virulence.

Video: Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Distinct species of Leishmania, a protozoan parasite of the family Trypanosomatidae, typically cause different human disease manifestations. The most common forms of disease are visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). Mouse models of leishmaniasis are widely used, but quantification of parasite burdens during murine disease requires mice to be euthanized at various times after infection. Parasite loads are then measured either by microscopy, limiting dilution assay, or qPCR amplification of parasite DNA. The in vivo imaging system (IVIS) has an integrated software package that allows the detection of a bioluminescent signal associated with cells in living organisms. Both to minimize animal usage and to follow infection longitudinally in individuals, in vivo models for imaging Leishmania spp. causing VL or CL were established. Parasites were engineered to express luciferase, and these were introduced into mice either intradermally or intravenously. Quantitative measurements of the luciferase driving bioluminescence of the transgenic Leishmania parasites within the mouse were made using IVIS. Individual mice can be imaged multiple times during longitudinal studies, allowing us to assess the inter-animal variation in the initial experimental parasite inocula, and to assess the multiplication of parasites in mouse tissues. Parasites are detected with high sensitivity in cutaneous locations. Although it is very likely that the signal (photons/second/parasite) is lower in deeper visceral organs than the skin, but quantitative comparisons of signals in superficial versus deep sites have not been done. It is possible that parasite numbers between body sites cannot be directly compared, although parasite loads in the same tissues can be compared between mice. Examples of one visceralizing species (L. infantum chagasi) and one species causing cutaneous leishmaniasis (L. mexicana) are shown. The IVIS procedure can be used for monitoring and analyzing small animal models of a wide variety of Leishmania species causing the different forms of human leishmaniasis.

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

An in vivo imaging system is used to generate quantitative measurements of murine infection with the Trypanosomatid protozoan Leishmania. This is a non-invasive and non-lethal method for detecting parasites expressing luciferase within many tissues throughout the course of chronic Leishmania spp. infection.

Distinct species of Leishmania, a protozoan parasite of the family Trypanosomatidae, typically cause different human disease manifestations. The most ...

Protocol for Production of a Genetic Cross of the Rodent Malaria Parasites

Variation in response to antimalarial drugs and in pathogenicity of malaria parasites is of biologic and medical importance. Linkage mapping has led to successful identification of genes or loci underlying various traits in malaria parasites of rodents1-3 and humans4-6. The malaria parasite Plasmodium yoelii is one of many malaria species isolated from wild African rodents and has been adapted to grow in laboratories. This species reproduces many of the biologic characteristics of the human malaria parasites; genetic markers such as microsatellite and amplified fragment length polymorphism (AFLP) markers have also been developed for the parasite7-9. Thus, genetic studies in rodent malaria parasites can be performed to complement research on Plasmodium falciparum. Here, we demonstrate the techniques for producing a genetic cross in P. yoelii that were first pioneered by Drs. David Walliker, Richard Carter, and colleagues at the University of Edinburgh10.

Genetic crosses in P. yoelii and other rodent malaria parasites are conducted by infecting mice Mus musculus with an inoculum containing gametocytes of two genetically distinct clones that differ in phenotypes of interest and by allowing mosquitoes to feed on the infected mice 4 days after infection. The presence of male and female gametocytes in the mouse blood is microscopically confirmed before feeding. Within 48 hrs after feeding, in the midgut of the mosquito, the haploid gametocytes differentiate into male and female gametes, fertilize, and form a diploid zygote (Fig. 1). During development of a zygote into an ookinete, meiosis appears to occur11. If the zygote is derived through cross-fertilization between gametes of the two genetically distinct parasites, genetic exchanges (chromosomal reassortment and cross-overs between the non-sister chromatids of a pair of homologous chromosomes; Fig. 2) may occur, resulting in recombination of genetic material at homologous loci. Each zygote undergoes two successive nuclear divisions, leading to four haploid nuclei. An ookinete further develops into an oocyst. Once the oocyst matures, thousands of sporozoites (the progeny of the cross) are formed and released into mosquito hemoceal. Sporozoites are harvested from the salivary glands and injected into a new murine host, where pre-erythrocytic and erythrocytic stage development takes place. Erythrocytic forms are cloned and classified with regard to the characters distinguishing the parental lines prior to genetic linkage mapping. Control infections of individual parental clones are performed in the same way as the production of a genetic cross.

Genetic crosses of rodent malaria parasites are performed by feeding two genetically distinct parasites to mosquitoes. Recombinant progeny are cloned from mouse blood after allowing mosquitoes to bite infected mice. This video shows how to produce genetic crosses of Plasmodium yoelii and is applicable to other rodent malaria parasites.

Variation in response to antimalarial drugs and in pathogenicity of malaria parasites is of biologic and medical importance. Linkage mapping has led to ...

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Leishmaniasis is one of the world's most neglected diseases, largely affecting the poorest of the poor, mainly in developing countries. Over 350 million people are considered at risk of contracting leishmaniasis, and approximately 2 million new cases occur yearly1. Leishmania donovani is the causative agent for visceral leishmaniasis (VL), the most fatal form of the disease. The choice of drugs available to treat leishmaniasis is limited 2;current treatments provide limited efficacy and many are toxic at therapeutic doses. In addition, most of the first line treatment drugs have already lost their utility due to increasing multiple drug resistance 3. The current pipeline of anti-leishmanial drugs is also severely depleted. Sustained efforts are needed to enrich a new anti-leishmanial drug discovery pipeline, and this endeavor relies on the availability of suitable in vitro screening models.
In vitro promastigotes 4 and axenic amastigotes assays5 are primarily used for anti-leishmanial drug screening however, may not be appropriate due to significant cellular, physiological, biochemical and molecular differences in comparison to intracellular amastigotes. Assays with macrophage-amastigotes models are considered closest to the pathophysiological conditions of leishmaniasis, and are therefore the most appropriate for in vitro screening. Differentiated, non-dividing human acute monocytic leukemia cells (THP1) (make an attractive) alternative to isolated primary macrophages and can be used for assaying anti-leishmanial activity of different compounds against intracellular amastigotes.
Here, we present a parasite-rescue and transformation assay with differentiated THP1 cells infected in vitro with Leishmania donovani for screening pure compounds and natural products extracts and determining the efficacy against the intracellular Leishmania amastigotes. The assay involves the following steps: (1) differentiation of THP1 cells to non-dividing macrophages, (2) infection of macrophages with L. donovani metacyclic promastigotes, (3) treatment of infected cells with test drugs, (4) controlled lysis of infected macrophages, (5) release/rescue of amastigotes and (6) transformation of live amastigotes to promastigotes. The assay was optimized using detergent treatment for controlled lysis of Leishmania-infected THP1 cells to achieve almost complete rescue of viable intracellular amastigotes with minimal effect on their ability to transform to promastigotes. Different macrophage:promastigotes ratios were tested to achieve maximum infection. Quantification of the infection was performed through transformation of live, rescued Leishmania amastigotes to promastigotes and evaluation of their growth by an alamarBlue fluorometric assay in 96-well microplates. This assay is comparable to the currently-used microscopic, transgenic reporter gene and digital-image analysis assays. This assay is robust and measures only the live intracellular amastigotes compared to reporter gene and image analysis assays, which may not differentiate between live and dead amastigotes. Also, the assay has been validated with a current panel of anti-leishmanial drugs and has been successfully applied to large-scale screening of pure compounds and a library of natural products fractions (Tekwani et al. unpublished).

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

A parasite-rescue and transformation assay with THP1 cells infected in vitro with Leishmania donovani has been optimized for anti-leishmanial drug screening. The assay involves differentiation of THP1 cells, infection with promastigotes, treatment with test drugs, controlled lysis of the infected macrophages, rescue of amastigotes, transformation to promastigotes and monitoring promastigote growth and proliferation with a fluorometric assay.

Leishmaniasis is  one of the world's most neglected diseases, largely affecting the  poorest of the poor, mainly in developing countries. Over 350 million ...

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Leishmania spp. are protozoan parasites that cause leishmaniases, diseases that present a wide spectrum of clinical manifestations from cutaneous to visceral lesions. Currently, 12 million people are estimated to be infected with Leishmania worldwide and over 1 billion people live at the risk of infection. Leishmania amazonensis is endemic in Central and South America and usually leads to the cutaneous form of the disease, which can be directly visualized in an animal model. Therefore, L. amazonensis strains are good models for cutaneous leishmaniasis studies because they are also easily cultivated in vitro. C57BL/6 mice mimic the L. amazonensis-driven disease progression observed in humans and are considered one of the best mice strains model for cutaneous leishmaniasis. In the vertebrate host, these parasites inhabit macrophages despite the defense mechanisms of these cells. Several studies use in vitro macrophage infection assays to evaluate the parasite infectivity under different conditions. However, the in vitro approach is limited to an isolated cell system that disregards the organism&#39;s response. Here, we compile an in vivo murine infection method that provides a systemic physiological overview of the host-parasite interaction. The detailed protocol for the in vivo infection of C57BL/6 mice with L. amazonensis comprises parasite differentiation into infective amastigotes, mice footpad cutaneous inoculation, lesion development, and parasite load determination. We propose this well-established method as the most adequate method for physiological studies of the host immune and metabolic responses to cutaneous leishmaniasis.

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Here, we present a compiled protocol to evaluate the cutaneous infection of mice with Leishmania amazonensis. This is a reliable method for studying parasite virulence, allowing a systemic view of the vertebrate host response to the infection.

Leishmania spp. are protozoan parasites that cause leishmaniases, diseases that present a wide spectrum of clinical manifestations from cutaneous to ...

Investigating the Phagocytosis of Leishmania using Confocal Microscopy

Phagocytosis is an orchestrated process that involves distinct steps: recognition, binding, and internalization. Professional phagocytes take up Leishmania parasites by phagocytosis, consisting of recognizing ligands on parasite surfaces by multiple host cell receptors. Binding of Leishmania to macrophage membranes occurs through complement receptor type 1 (CR1) and complement receptor type 3 (CR3) and Pattern Recognition Receptors. Lipophosphoglycan (LPG) and 63 kDa glycoprotein (gp63) are the main ligands involved in macrophage-Leishmania interactions. Following the initial recognition of parasite ligands by host cell receptors, parasites become internalized, survive, and multiply within parasitophorous vacuoles. The maturation process of Leishmania-induced vacuoles involves the acquisition of molecules from intracellular vesicles, including monomeric G protein Rab 5 and Rab 7, lysosomal associated membrane protein 1 (LAMP-1), lysosomal associated membrane protein 2 (LAMP-2), and microtubule-associated protein 1A/1B-light chain 3 (LC3).
Here, we describe methods to evaluate the early events occurring during Leishmania interaction with the host cells using confocal microscopy, including (i) binding (ii) internalization, and (iii) phagosome maturation. By adding to the body of knowledge surrounding these determinants of infection outcome, we hope to improve the understanding of the pathogenesis of Leishmania infection and support the eventual search for novel chemotherapeutic targets.

Investigating the Phagocytosis of Leishmania using Confocal Microscopy

The mechanism associated with phagocytosis in Leishmania infection remains poorly understood. Here, we describe methods to evaluate the early events occurring during Leishmania interaction with the host cells.

Phagocytosis is an orchestrated process that involves distinct steps: recognition, binding, and internalization. Professional phagocytes take up ...

Obtainment of Macrophages from Human Monocytes to Assess Leishmania braziliensis Infection Rate and Innate Host Immune Response

Macrophages are multifunctional cells essential to the immune system function, and the primary host cell in Leishmania braziliensis (Lb) infection. These cells are specialized in microorganism recognition and phagocytosis, but also activate other immune cells and present antigens, as well as promote inflammation and tissue repair. Here, we describe a protocol to obtain mononuclear cells from peripheral blood (PBMC) of healthy donors to separate monocytes that then differentiate into macrophages. These cells can then be infected in vitro at different Lb concentrations to evaluate the ability to control infection, as well as evaluate host cell immune response, which can be measured by several methods. PBMCs were first isolated by centrifuging with Ficoll-Hypaque gradient and then plated to allow monocytes to adhere to culture plates; non-adherent cells were removed by washing. Next, adherent cells were cultured with macrophage-colony stimulating factor (M-CSF) for 7 days to induce macrophage differentiation. We suggest plating 2 x 106&#160;cells per well on 24-well plates in order to obtain 2 x 105&#160;macrophages. Fully differentiated macrophages can then be infected with Lb for 4 or 24 hours. This protocol results in a significant percentage of infected cells, which can be assessed by optical or fluorescence microscopy. In addition to infection index, parasite load can be measured by counting the numbers of parasites inside each cell. Further molecular and functional assays can also be performed in culture supernatants or within the macrophages themselves, which allows this protocol to be applied in a variety of contexts and also adapted to other intracellular parasite species.

Obtainment of Macrophages from Human Monocytes to Assess Leishmania braziliensis Infection Rate and Innate Host Immune Response

This protocol describes the process for obtaining human macrophages from monocytes for infection with Leishmania braziliensis. It also allows researchers to evaluate infection rate and parasite viability, ROS production by fluorescence microscopy, and the production of inflammatory mediators in culture supernatants to investigate macrophage response to infection.

Macrophages are multifunctional cells essential to the immune system function, and the primary host cell in Leishmania braziliensis (Lb) infection. These ...

In Vitro Differentiation of Human Dendritic Cells and their Markers in Leishmania Infection

Leishmaniasis comprises a collection of clinical manifestations associated with the infection of obligate intracellular protozoans, Leishmania. The life cycle of Leishmania parasites consists of two alternating life stages (amastigotes and promastigotes), during which parasites reside within either arthropod vectors or vertebrate hosts, respectively. Notably, the complex interactions between Leishmania parasites and several cells of the immune system largely influence the outcome of infection. Importantly, although macrophages are known to be the main host niche for Leishmania replication, parasites are also phagocytosed by other innate immune cells, such as neutrophils and dendritic cells (DCs). 
DCs play a major role in bridging the innate and adaptive branches of immunity and thus orchestrate immune responses against a wide range of pathogens. The mechanisms by which Leishmania and DCs interact remain unclear and involve aspects of pathogen capture, the dynamics of DC maturation and activation, DC migration to draining lymph node (dLNs), and antigen presentation to T cells. Although a large body of studies support the notion that DCs play a dual role in modulating immune responses against Leishmania, the participation of these cells in susceptibility or resistance to Leishmania remains poorly understood. After infection, DCs undergo a maturation process associated with the upregulation of surface major histocompatibility complex (MHC) II, in addition to costimulatory molecules (namely, CD40, CD80, and CD86). 
Understanding the role of DCs in infection outcome is crucial to developing therapeutic and prophylactic strategies to modulate the immune response against Leishmania. This paper describes a method for the characterization of Leishmania-DC interaction. This detailed protocol provides guidance throughout the steps of DC differentiation, the characterization of cell surface molecules, and infection protocols, allowing scientists to investigate DC response to Leishmania infection and gain insight into the roles played by these cells in the course of infection.

In Vitro Differentiation of Human Dendritic Cells and their Markers in Leishmania Infection

Dendritic cells (DCs) are essential components of innate immunity against Leishmania infection. The mechanisms underlying the complex interaction between DCs and Leishmania remain poorly understood. Here, we describe methods to evaluate how Leishmania infection affects the immunobiological function of human DCs, such as migration-related and costimulatory molecule expression.

Leishmaniasis comprises a collection of clinical manifestations associated with the infection of obligate intracellular protozoans, Leishmania. The life ...

In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase

American tegumentary leishmaniasis (ATL) and visceral leishmaniasis (VL) are considered neglected by the World Health Organization. VL can be lethal if not treated; the drugs used in treatment are toxic, and there are cases of resistance. Preclinical tests can represent a bottleneck in discovering new medicines for treatment, depending on the animal model, the strain used, and the inoculum route. The golden hamster stands out for its high susceptibility to subgenera Viannia and Leishmania species, displaying many of the clinical and immunopathological processes observed in human disease.
By hamster anatomy, which has a short tail and limbs, the intracardiac route is usually the choice for intravenous injection of Leishmania. However, it is an inoculum that can lead to bleeding and eventually to animal death. Thus, we standardized an alternative intravenous inoculation route for infection at the gingival vein, which is minimally invasive, allows easy venous access, and causes few local and systemic injuries to the animal. Therefore, hamsters infected by the intraperitoneal (IP) or intragingival (IG) route with Leishmania Infantum expressing luciferase (Luc) were followed up for 22 days by the bioluminescence imaging system and 50 days and 8 months post infection by PCR.
After gingival inoculation of both axenic amastigotes and promastigotes of L. infantum-Luc, bioluminescence was restricted for at least 2 weeks at the site of injection, which is an indicator of infection in the tissues around the gingival plexus. Hamsters infected intraperitoneally with L. infantum-Luc displayed bioluminescence dispersed throughout the abdomen, as expected. However, by the bioluminescence imaging system infection declined until the 50th dpi and was only detectable by PCR.&#160;Axenic amastigotes showed better infection than promastigotes, as evaluated by PCR. Indeed, 8 months after infection, parasites were detected by PCR in the liver of animals inoculated with axenic amastigotes by the intravenous route, which can be a characteristic of the reference strain of L. infantum MHOM/BR/1974/PP75, whose infection progresses slowly and display low parasite burden, below the bioluminescent imaging resolution. Thus, axenic amastigotes can be a better choice for infection and follow-up than promastigotes, and the gingival inoculum is a feasible route for intravenous injection of Leishmania and other pathogens.

Here we present a longitudinal evaluation of golden hamsters infected intraperitoneally (IP) or via intragingival (IG) with L. infantum-Luc by bioluminescent imaging and by PCR. Hamsters were evaluated 1 day post infection (1 dpi), 1 week after infection (8 dpi), and 3 weeks after infection (22 dpi) and euthanized at the 50th dpi and 8 months post infection.

American tegumentary leishmaniasis (ATL) and visceral leishmaniasis (VL) are considered neglected by the World Health Organization. VL can be lethal if ...

Biology

Assessment of Leishmania Virulence within Cultured Macrophages

Source: Sarkar, A. et al., <a href="https://appjove.unicartagenaproxy.elogim.com/v/57486">Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of&#160;Leishmania&#160;Parasites.</a>&#160;J. Vis. Exp.&#160;(2018)
This video investigates Leishmania&#39;s virulence by treating macrophages with metacyclic promastigotes, resulting in the formation of intracellular amastigotes. The confirmation of Leishmania&#39;s virulence is achieved through nucleic acid fluorescent dye staining. This insight can contribute to the development of new therapies for leishmaniasis.

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. ...

JoVE Encyclopedia of Experiments

Immunology

Immunodiagnostics

Imaging and Visualization Techniques

An In Vitro Assay to Quantify the Intracellular Growth of Parasite in Macrophages

Source: Sarkar, A., et al. <a href="https://appjove.unicartagenaproxy.elogim.com/v/57486">Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites.</a> J. Vis. Exp. (2018).
This video demonstrates an assay to quantify the intracellular growth of parasites in bone marrow-derived macrophages (BMMs). The macrophage cells are infected with the motile and non-motile invasive stages of Leishmania, metacyclic promastigotes and amastigotes, respectively. The parasites invade the macrophages, getting internalized into a parasitophorous vacuole and multiplying inside. The intracellular parasite growth is quantified using a microscope upon fluorescently staining the macrophage and parasite nuclei.

1. Plating BMMs on Coverslips for Infection 

	Prepare 6-well tissue culture plates by placing four (4) sterile 12 mm glass coverslips (autoclaved and ...

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

Summary

Explore More Videos

Chapters in this video

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Protocol for Production of a Genetic Cross of the Rodent Malaria Parasites

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Investigating the Phagocytosis of Leishmania using Confocal Microscopy

Obtainment of Macrophages from Human Monocytes to Assess Leishmania braziliensis Infection Rate and Innate Host Immune Response

In Vitro Differentiation of Human Dendritic Cells and their Markers in Leishmania Infection

In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase

Assessment of Leishmania Virulence within Cultured Macrophages

An In Vitro Assay to Quantify the Intracellular Growth of Parasite in Macrophages